South Korea grants first approval worldwide to a stem cell therapy
This article was originally published in SRA
South Korea's Food and Drug Administration has granted the first commercial clearance in a regulated market to a therapy based on adult stem cells, awarding a marketing approval to FCB-Pharmicell's acute myocardial infarction (AMI) product Hearticellgram-AMI.
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.